Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.45
NAS:CLVS's Cash-to-Debt is ranked lower than
82% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:CLVS: 1.45 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CLVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.91  Med: N/A Max: No Debt
Current: 1.45
Equity-to-Asset 0.33
NAS:CLVS's Equity-to-Asset is ranked lower than
99.99% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:CLVS: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CLVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.54 Max: 0.75
Current: 0.33
0.33
0.75
Piotroski F-Score: 4
Altman Z-Score: -0.34
Beneish M-Score: -3.53
WACC vs ROIC
12.13%
-992.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -4882.09
NAS:CLVS's Operating Margin % is ranked lower than
99.99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:CLVS: -4882.09 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CLVS' s Operating Margin % Range Over the Past 10 Years
Min: -477862.82  Med: -239512.91 Max: -1163
Current: -4882.09
-477862.82
-1163
Net Margin % -4601.86
NAS:CLVS's Net Margin % is ranked lower than
99.99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:CLVS: -4601.86 )
Ranked among companies with meaningful Net Margin % only.
NAS:CLVS' s Net Margin % Range Over the Past 10 Years
Min: -447611.54  Med: -224393.04 Max: -1174.54
Current: -4601.86
-447611.54
-1174.54
ROE % -282.84
NAS:CLVS's ROE % is ranked lower than
92% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:CLVS: -282.84 )
Ranked among companies with meaningful ROE % only.
NAS:CLVS' s ROE % Range Over the Past 10 Years
Min: -282.84  Med: -83.7 Max: -26.78
Current: -282.84
-282.84
-26.78
ROA % -67.20
NAS:CLVS's ROA % is ranked lower than
77% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:CLVS: -67.20 )
Ranked among companies with meaningful ROA % only.
NAS:CLVS' s ROA % Range Over the Past 10 Years
Min: -144.39  Med: -51.12 Max: -21.25
Current: -67.2
-144.39
-21.25
ROC (Joel Greenblatt) % -7315.48
NAS:CLVS's ROC (Joel Greenblatt) % is ranked lower than
85% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:CLVS: -7315.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CLVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9748.56  Med: -7941.19 Max: -3834.63
Current: -7315.48
-9748.56
-3834.63
3-Year EBITDA Growth Rate 48.70
NAS:CLVS's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:CLVS: 48.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CLVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.4  Med: 8.65 Max: 51.8
Current: 48.7
-53.4
51.8
3-Year EPS without NRI Growth Rate 45.40
NAS:CLVS's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:CLVS: 45.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CLVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.1  Med: 7.15 Max: 48.8
Current: 45.4
-53.1
48.8
GuruFocus has detected 2 Warning Signs with Clovis Oncology Inc $NAS:CLVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CLVS's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CLVS Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
Kyle Bass Sold Out
Jim Simons 307,200 sh (-40.40%)
» More
Q3 2016

CLVS Guru Trades in Q3 2016

Louis Moore Bacon 95,000 sh (New)
Columbia Wanger 204,000 sh (New)
Jim Simons Sold Out
» More
Q4 2016

CLVS Guru Trades in Q4 2016

Chuck Royce 76,000 sh (New)
Jim Simons 82,100 sh (New)
John Burbank 381,814 sh (New)
Columbia Wanger 189,958 sh (-6.88%)
» More
Q1 2017

CLVS Guru Trades in Q1 2017

Jim Simons 153,400 sh (+86.85%)
Chuck Royce 76,000 sh (unchged)
Columbia Wanger Sold Out
John Burbank 202,804 sh (-46.88%)
Louis Moore Bacon 40,000 sh (-57.89%)
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NYSE:AXON, NAS:AGIO, NAS:LGND, NAS:RARE, NAS:SAGE, NAS:PTLA, NAS:PRTA, NAS:JUNO, OTCPK:ABCZY, NAS:TBPH, OTCPK:MPSYY, NAS:SRPT, NAS:AVXS, NAS:FGEN, NAS:ICPT, NYSE:XON, NAS:NKTR, NAS:DBVT, NYSE:CBM, OTCPK:BVNRY » details
Traded in other countries:C6O.Germany,
Headquarter Location:USA
Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its commercial product is Rubraca.

Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.

Ratios

vs
industry
vs
history
PB Ratio 13.92
CLVS's PB Ratio is ranked lower than
99.99% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CLVS: 13.92 )
Ranked among companies with meaningful PB Ratio only.
CLVS' s PB Ratio Range Over the Past 10 Years
Min: 1.28  Med: 4.24 Max: 18.03
Current: 13.92
1.28
18.03
PS Ratio 343.65
CLVS's PS Ratio is ranked lower than
99.99% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CLVS: 343.65 )
Ranked among companies with meaningful PS Ratio only.
CLVS' s PS Ratio Range Over the Past 10 Years
Min: 31.02  Med: 127.07 Max: 445.75
Current: 343.65
31.02
445.75
EV-to-EBIT -6.82
CLVS's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CLVS: -6.82 )
Ranked among companies with meaningful EV-to-EBIT only.
CLVS' s EV-to-EBIT Range Over the Past 10 Years
Min: -26  Med: -10.1 Max: -1.4
Current: -6.82
-26
-1.4
EV-to-EBITDA -6.85
CLVS's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CLVS: -6.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27  Med: -10.4 Max: -1.5
Current: -6.85
-27
-1.5
Current Ratio 7.28
CLVS's Current Ratio is ranked higher than
52% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CLVS: 7.28 )
Ranked among companies with meaningful Current Ratio only.
CLVS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 9.19 Max: 31.09
Current: 7.28
0.86
31.09
Quick Ratio 7.17
CLVS's Quick Ratio is ranked higher than
53% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CLVS: 7.17 )
Ranked among companies with meaningful Quick Ratio only.
CLVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 9.19 Max: 31.09
Current: 7.17
0.86
31.09
Days Inventory 309.31
CLVS's Days Inventory is ranked lower than
99.99% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CLVS: 309.31 )
Ranked among companies with meaningful Days Inventory only.
CLVS' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 309.31
Current: 309.31
0
309.31
Days Sales Outstanding 123.20
CLVS's Days Sales Outstanding is ranked lower than
99.99% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CLVS: 123.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.86  Med: 313.54 Max: 566.22
Current: 123.2
60.86
566.22
Days Payable 5.00
CLVS's Days Payable is ranked lower than
99.99% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CLVS: 5.00 )
Ranked among companies with meaningful Days Payable only.
CLVS' s Days Payable Range Over the Past 10 Years
Min: 5  Med: 56898.29 Max: 56898.29
Current: 5
5
56898.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
CLVS's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CLVS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -194.7  Med: -14.2 Max: -4.5
Current: -4.5
-194.7
-4.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 52.36
CLVS's Price-to-Net-Cash is ranked lower than
99.99% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CLVS: 52.36 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CLVS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 11.59 Max: 52.82
Current: 52.36
0
52.82
Price-to-Net-Current-Asset-Value 36.41
CLVS's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CLVS: 36.41 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CLVS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 10.57 Max: 41.79
Current: 36.41
0
41.79
Price-to-Tangible-Book 25.34
CLVS's Price-to-Tangible-Book is ranked lower than
99.99% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CLVS: 25.34 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CLVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.39  Med: 9.86 Max: 396.95
Current: 25.34
2.39
396.95
Price-to-Median-PS-Value 2.70
CLVS's Price-to-Median-PS-Value is ranked lower than
99.99% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CLVS: 2.70 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CLVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1 Max: 2.73
Current: 2.7
0
2.73
Earnings Yield (Greenblatt) % -14.70
CLVS's Earnings Yield (Greenblatt) % is ranked lower than
65% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CLVS: -14.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CLVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -584.77  Med: 0 Max: 0
Current: -14.7
-584.77
0

More Statistics

Revenue (TTM) (Mil) $7.05
EPS (TTM) $ -8.23
Beta1.83
Short Percentage of Float20.67%
52-Week Range $11.57 - 74.94
Shares Outstanding (Mil)44.77
» More Articles for NAS:CLVS

Headlines

Articles On GuruFocus.com
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test Apr 27 2017 
Kyle Bass Purchases Stake in Clovis Oncology May 25 2016 
Kyle Bass Builds Bull Case for Clovis Oncology Nov 27 2015 
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
VBI Vaccines (VBIV) and Clovis Oncology (CLVS) Momentum Indicators; Wynn Resorts (WYNN) Power Battle Apr 07 2015 

More From Other Websites
Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting May 23 2017
Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain May 22 2017
Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug? May 17 2017
Edited Transcript of CLVS earnings conference call or presentation 3-May-17 8:30pm GMT May 12 2017
How Clovis Might Still Quash AstraZeneca, Tesaro In Cancer May 04 2017
Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update May 04 2017
Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start May 04 2017
Clovis reports 1Q loss May 03 2017
Clovis Oncology Announces First Quarter 2017 Operating Results May 03 2017
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test... Apr 27 2017
Tesaro Inc Bulls Need a Reality Check Apr 25 2017
Tesaro's Path to a Billion-Dollar Blockbuster Begins With Pricing Apr 21 2017
Tesaro’s Zejula Flops as H&S Pattern Emerges Apr 21 2017
Tesaro Dives On 'Sticker Shock' For $177,000 Drug Apr 20 2017
AbbVie's PARP Inhibitor Comes Up Empty Apr 20 2017
Clovis Oncology to Announce First Quarter 2017 Financial Results and Host Webcast Conference Call on... Apr 20 2017
3 Cancer Drug Stocks That Could Make You Rich Apr 17 2017
Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology Apr 10 2017
Why Clovis Oncology's Stock Edged Higher in March Apr 07 2017
Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : March 31,... Mar 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat